USD 0.6
(-0.84%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | -212 Thousand USD | 47.65% |
2022 | -405 Thousand USD | -97.56% |
2021 | -205 Thousand USD | -38.51% |
2020 | -148 Thousand USD | -28.7% |
2019 | -115 Thousand USD | 22.3% |
2018 | -148 Thousand USD | 5.73% |
2017 | -157 Thousand USD | -237.72% |
2016 | 114 Thousand USD | 40.74% |
2015 | 81 Thousand USD | 110.28% |
2014 | -788 Thousand USD | 0.0% |
2013 | - USD | 0.0% |
2012 | - USD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 Q4 | -22 Thousand USD | 0.0% |
2023 Q2 | -95 Thousand USD | 0.0% |
2023 FY | -212 Thousand USD | 47.65% |
2023 Q1 | -95 Thousand USD | 0.0% |
2023 Q3 | - USD | 100.0% |
2022 FY | -405 Thousand USD | -97.56% |
2022 Q3 | - USD | 0.0% |
2022 Q4 | - USD | 0.0% |
2022 Q2 | - USD | 0.0% |
2022 Q1 | - USD | 100.0% |
2021 Q3 | -50 Thousand USD | -8.7% |
2021 Q2 | -46 Thousand USD | -6.98% |
2021 FY | -205 Thousand USD | -38.51% |
2021 Q4 | -66 Thousand USD | -32.0% |
2021 Q1 | -43 Thousand USD | -4.88% |
2020 Q4 | -41 Thousand USD | 0.0% |
2020 Q1 | - USD | 0.0% |
2020 Q2 | - USD | 0.0% |
2020 Q3 | - USD | 0.0% |
2020 FY | -148 Thousand USD | -28.7% |
2019 Q2 | - USD | 0.0% |
2019 FY | -115 Thousand USD | 22.3% |
2019 Q3 | - USD | 0.0% |
2019 Q1 | - USD | 0.0% |
2019 Q4 | - USD | 0.0% |
2018 Q3 | - USD | 0.0% |
2018 FY | -148 Thousand USD | 5.73% |
2018 Q4 | - USD | 0.0% |
2018 Q2 | - USD | 0.0% |
2018 Q1 | - USD | 0.0% |
2017 Q2 | - USD | 0.0% |
2017 Q3 | - USD | 0.0% |
2017 Q4 | - USD | 0.0% |
2017 FY | -157 Thousand USD | -237.72% |
2017 Q1 | - USD | -100.0% |
2016 Q3 | - USD | 0.0% |
2016 FY | 114 Thousand USD | 40.74% |
2016 Q1 | - USD | -100.0% |
2016 Q2 | - USD | 0.0% |
2016 Q4 | 244 Thousand USD | 0.0% |
2015 Q2 | - USD | 0.0% |
2015 Q1 | - USD | 100.0% |
2015 Q4 | 173 Thousand USD | 0.0% |
2015 Q3 | - USD | 0.0% |
2015 FY | 81 Thousand USD | 110.28% |
2014 Q3 | - USD | 0.0% |
2014 Q1 | - USD | 0.0% |
2014 Q2 | - USD | 0.0% |
2014 Q4 | -788 Thousand USD | 0.0% |
2014 FY | -788 Thousand USD | 0.0% |
2013 Q2 | - USD | 0.0% |
2013 Q4 | - USD | 0.0% |
2013 FY | - USD | 0.0% |
2013 Q1 | - USD | 0.0% |
2013 Q3 | - USD | 0.0% |
2012 FY | - USD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Bionano Genomics, Inc. | 9.56 Million USD | 102.216% |
Prenetics Global Limited | 8.82 Million USD | 102.401% |
Star Equity Holdings, Inc. | 11.92 Million USD | 101.778% |
CareDx, Inc | 178.32 Million USD | 100.119% |
Exact Sciences Corporation | 1.84 Billion USD | 100.011% |
Exagen Inc. | 29.45 Million USD | 100.72% |
Inotiv, Inc. | 165.44 Million USD | 100.128% |
Guardant Health, Inc. | 336.89 Million USD | 100.063% |
Biodesix, Inc. | 36.07 Million USD | 100.588% |
BioNexus Gene Lab Corp. | 1.32 Million USD | 115.946% |
Precipio, Inc. | 6.01 Million USD | 103.523% |
iSpecimen Inc. | 5.1 Million USD | 104.15% |
Natera, Inc. | 492.74 Million USD | 100.043% |
Aspira Women's Health Inc. | 5.26 Million USD | 104.029% |
Standard BioTools Inc. | 50.45 Million USD | 100.42% |
23andMe Holding Co. | 99.37 Million USD | 100.213% |
Castle Biosciences, Inc. | 174.8 Million USD | 100.121% |
Personalis, Inc. | 18.2 Million USD | 101.164% |
Aclaris Therapeutics, Inc. | 13.16 Million USD | 101.61% |
Applied DNA Sciences, Inc. | 5.53 Million USD | 103.831% |
OpGen, Inc. | -90.69 Thousand USD | -133.753% |
T2 Biosystems, Inc. | -8.17 Million USD | 97.405% |
Myriad Genetics, Inc. | 476.4 Million USD | 100.045% |
ICON Public Limited Company | 1.81 Billion USD | 100.012% |
NeoGenomics, Inc. | 244.6 Million USD | 100.087% |
Star Equity Holdings, Inc. | 11.92 Million USD | 101.778% |
IDEXX Laboratories, Inc. | 2.18 Billion USD | 100.01% |
RadNet, Inc. | 93 Million USD | 100.228% |
MDxHealth SA | 43.92 Million USD | 100.483% |
Psychemedics Corporation | 8.41 Million USD | 102.52% |
Illumina, Inc. | 2.74 Billion USD | 100.008% |
Twist Bioscience Corporation | 133.34 Million USD | 100.159% |
DarioHealth Corp. | 5.98 Million USD | 103.543% |
Fulgent Genetics, Inc. | 104.45 Million USD | 100.203% |
Sera Prognostics, Inc. | 96 Thousand USD | 320.833% |
ENDRA Life Sciences Inc. | -275.45 Thousand USD | 23.035% |
OPKO Health, Inc. | 318.12 Million USD | 100.067% |
Medpace Holdings, Inc. | 524.5 Million USD | 100.04% |
Neogen Corporation | 463.9 Million USD | 100.046% |
Intelligent Bio Solutions Inc. | 1.42 Million USD | 114.871% |
Prenetics Global Limited | 8.82 Million USD | 102.401% |
Mainz Biomed B.V. | 509.65 Thousand USD | 141.596% |
bioAffinity Technologies, Inc. | 791.61 Thousand USD | 126.781% |
Trinity Biotech plc | 19.45 Million USD | 101.09% |
Neuronetics, Inc. | 51.7 Million USD | 100.41% |
Sotera Health Company | 577.15 Million USD | 100.037% |
bioAffinity Technologies, Inc. | 791.61 Thousand USD | 126.781% |